137 related articles for article (PubMed ID: 8119275)
1. Effect of long-term vigabatrin therapy on GABA and other amino acid concentrations in the central nervous system--a case study.
Ben-Menachem E; Hamberger A; Mumford J
Epilepsy Res; 1993 Dec; 16(3):241-3. PubMed ID: 8119275
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids in humans.
Ben-Menachem E
Epilepsia; 1989; 30 Suppl 3():S12-4. PubMed ID: 2767013
[TBL] [Abstract][Full Text] [Related]
3. Effect of vigabatrin (gamma-vinyl GABA) on amino acid levels in CSF of epileptic patients.
Pitkänen A; Matilainen R; Ruutiainen T; Lehtinen M; Riekkinen P
J Neurol Neurosurg Psychiatry; 1988 Nov; 51(11):1395-400. PubMed ID: 2853206
[TBL] [Abstract][Full Text] [Related]
4. Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy.
Menachem EB; Persson LI; Schechter PJ; Haegele KD; Huebert N; Hardenberg J; Dahlgren L; Mumford JP
Epilepsy Res; 1988; 2(2):96-101. PubMed ID: 3143561
[TBL] [Abstract][Full Text] [Related]
5. Effect of long-term vigabatrin therapy on selected neurotransmitter concentrations in cerebrospinal fluid.
Ben-Menachem E; Persson LI; Mumford J; Haegele KD; Huebert N
J Child Neurol; 1991; Suppl 2():S11-6. PubMed ID: 1719063
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory and excitatory amino acids in CSF of patients suffering from complex partial seizures during chronic treatment with gamma-vinyl GABA (vigabatrin).
Halonen T; Lehtinen M; Pitkänen A; Ylinen A; Riekkinen PJ
Epilepsy Res; 1988; 2(4):246-52. PubMed ID: 3143562
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma.
Löscher W; Hörstermann D
Naunyn Schmiedebergs Arch Pharmacol; 1994 Mar; 349(3):270-8. PubMed ID: 8208305
[TBL] [Abstract][Full Text] [Related]
8. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients.
Ben-Menachem E; Persson LI; Schechter PJ; Haegele KD; Huebert N; Hardenberg J; Dahlgren L; Mumford JP
Br J Clin Pharmacol; 1989; 27 Suppl 1(Suppl 1):79S-85S. PubMed ID: 2474312
[TBL] [Abstract][Full Text] [Related]
9. Vigabatrin: rational treatment for chronic epilepsy.
Ring HA; Heller AJ; Farr IN; Reynolds EH
J Neurol Neurosurg Psychiatry; 1990 Dec; 53(12):1051-5. PubMed ID: 2292696
[TBL] [Abstract][Full Text] [Related]
10. Administration of vigabatrin (gamma-vinyl-gamma-aminobutyric acid) affects the levels of both inhibitory and excitatory amino acids in rat cerebrospinal fluid.
Halonen T; Pitkänen A; Riekkinen PJ
J Neurochem; 1990 Dec; 55(6):1870-4. PubMed ID: 2230800
[TBL] [Abstract][Full Text] [Related]
11. Human brain gamma-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy.
Petroff OA; Behar KL; Mattson RH; Rothman DL
J Neurochem; 1996 Dec; 67(6):2399-404. PubMed ID: 8931472
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy.
Schechter PJ; Hanke NF; Grove J; Huebert N; Sjoerdsma A
Neurology; 1984 Feb; 34(2):182-6. PubMed ID: 6538006
[TBL] [Abstract][Full Text] [Related]
13. Effects of vigabatrin (gamma-vinyl GABA) on neurotransmission-related amino acids and on GABA and benzodiazepine receptor binding in rats.
Halonen T; Pitkänen A; Saano V; Riekkinen PJ
Epilepsia; 1991; 32(2):242-9. PubMed ID: 1672276
[TBL] [Abstract][Full Text] [Related]
14. Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.
Petroff OA; Rothman DL
Mol Neurobiol; 1998 Feb; 16(1):97-121. PubMed ID: 9554704
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid GABA and seizure control with vigabatrin.
Riekkinen PJ; Ylinen A; Halonen T; Sivenius J; Pitkanen A
Br J Clin Pharmacol; 1989; 27 Suppl 1(Suppl 1):87S-94S. PubMed ID: 2757914
[TBL] [Abstract][Full Text] [Related]
16. Vigabatrin.
Connelly JF
Ann Pharmacother; 1993 Feb; 27(2):197-204. PubMed ID: 8439699
[TBL] [Abstract][Full Text] [Related]
17. (4S)-4-amino-5,6-heptadienoic acid (MDL 72483): a potent anticonvulsant GABA-T inhibitor.
Sarhan S; Casara P; Knödgen B; Seiler N
Neurochem Res; 1991 Mar; 16(3):285-93. PubMed ID: 1780030
[TBL] [Abstract][Full Text] [Related]
18. Neuropathology of a human hippocampus following long-term treatment with vigabatrin: lack of microvacuoles.
Agosti R; Yasargil G; Egli M; Wieser HG; Wiestler OD
Epilepsy Res; 1990 Jul; 6(2):166-70. PubMed ID: 2387287
[TBL] [Abstract][Full Text] [Related]
19. Specificity of vigabatrin for the GABAergic system in human epilepsy.
Riekkinen PJ; Pitkanen A; Ylinen A; Sivenius J; Halonen T
Epilepsia; 1989; 30 Suppl 3():S18-22. PubMed ID: 2767015
[TBL] [Abstract][Full Text] [Related]
20. Determination of GABA and vigabatrin in human plasma by a rapid and simple HPLC method: correlation between clinical response to vigabatrin and increase in plasma GABA.
Löscher W; Fassbender CP; Gram L; Gramer M; Hörstermann D; Zahner B; Stefan H
Epilepsy Res; 1993 Mar; 14(3):245-55. PubMed ID: 8504795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
